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The experiments described in this paper tested the hypothesis whether iontophoresis applied on a chitosan nanoparticle formulation 
could combine the enhanced drug accumulation into the follicular casts obtained using iontophoresis and the sustained drug release, 
reducing dermal exposure, provided by nanoparticles. Results showed that even though iontophoresis presented comparable minoxidil 
targeting potential to hair follicles than passive delivery of chitosan-nanoparticles (4.1 ± 0.9 and 5.3 ± 1.0 µg cm-2, respectively), it 
was less effective on preventing dermal exposure, since chitosan-nanoparticles presented a drug permeation in the receptor solution of 
15.3 ± 4.3 µg cm-2 after 6 h of iontophoresis, while drug amounts from passive nanoparticle delivery were not detected. Drug release 
experiments showed particles were not able to sustain the drug release under the influence of a potential gradient. In conclusion, the 
application of MXS-loaded chitosan nanoparticles remains the best way to target MXS to the hair follicles while preventing dermal 
exposure.
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INTRODUCTION
Minoxidil application is already established as the standard treat-
ment for male and female androgenic alopecia. It is the only topical 
therapy with FDA’s approval and several products based on this drug 
are available in the market. Even though the exact mechanism of 
action remains uncertain, research has demonstrated that minoxidil 
is able to stimulate hair follicles, reversing their progressive minia-
turization associated with androgenic alopecia.1
Clinical trials have demonstrated that the success rate of the 
treatment with 5% minoxidil barely exceeds 40%.2 To elevate these 
indices, last researches have focused on developing more efficient 
formulations, i.e., formulations capable of targeting the active 
compound to hair follicles and sustaining its release.3 For this, solid 
lipid nanoparticles,4 penetration enhancer-containing vesicles5 and 
squarticles nanoparticles, formed from sebum-derived lipids,6 have 
been proposed. Although many studies have indeed demonstrated 
improved skin permeation, it is important to consider that minoxi-
dil, a pyridine-derivative, is a potent antihypertensive agent; hence, 
dermal exposure and a consequent systemic effect should be avoided 
to minimize adverse side effects.7
Our research group has recently reported a two-fold minoxi-
dil sulphate (MXS, Figure 1) increase into hair follicles with the 
application of MXS loaded in chitosan nanoparticles (MXS-NP) 
instead of the drug solution, which provided a sustained drug release 
and prevented dermal exposure.8 In this study, we have prepared 
and characterized MXS-NP and demonstrated that after passive 
treatment of porcine skin with this formulation, an enhancement 
in MXS penetration in hair follicles was observed compared to a 
simple solution of the drug. Moreover, it was not observed in any 
experiment significant concentrations of the drug in deeper skin 
layers.8 Other study of our group has observed that application of 
iontophoresis in a gel formulation containing the free drug, i.e., 
non-encapsulated MXS, increased by 5-fold the amount of drug 
reaching the follicular infundibula when compared with passive 
delivery, resulting therefore in a more pronounced target effect to 
the hair follicles.9 The drawback of this last approach, however, 
was that the increased targeting effect was also followed by a very 
significant drug transdermal transport, once a significant concen-
tration of MXS was recovered from epidermis and dermis in both 
tested skin models (porcine and rat skin).
Iontophoresis is a technique classically studied to increase and 
control the transport of hydrophilic and charged molecules into and 
through skin, by application of a mild direct current (of no more than 
0.5 mA/cm2).10,11 It has been currently used for topical and transdermal 
delivery of a great variety of drugs.12-16 The two main mechanisms 
involved in iontophoretic delivery of drugs are electromigration and 
electroosmosis. Both positively or negatively charged molecules are 
typically delivered by electromigration, as the charged drug stands 
in the same charged compartment, while neutral molecules can be 
transported via electroosmosis.10,11 As hair follicles and other skin ap-
pendices present lower electrical resistance for drug transport through 
the skin, it is well established in literature that molecules transported 
by iontophoresis follow the appendageal path.17
Some authors have recently evaluated the application of ion-
tophoresis to enhance skin permeation of drugs encapsulated in 
nanostructured particles,18-21 but the feasibility of this approach still 
remains inconclusive.
Figure 1. Chemical structure of MXS (2,4-diamine-6-piperidine- pyrimidi-
ne-3-oxide) (MW = 289.3 Da; pKa = 4.6)
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In this way, the aim of the experiments presented in this paper 
was to evaluate whether the application of iontophoresis to the MXS-
NP formulation could result in a maximum MXS delivery into the 
hair follicles, at the same time that could minimize transdermal drug 
absorption of the encapsulated drug.
EXPERIMENTAL
Material
MXS (99%) was kindly provided by Galena Química e 
Farmacêutica Ltda. (Campinas, Brazil). Low molecular weight 
chitosan (75–85% of deacetylation), acetic acid and sodium tripoly-
phosphate (TPP), used to prepare nanoparticles, were purchased from 
Sigma–Aldrich (Steinheim, Germany). Silver (Ag) wire (99.99%, ø = 
1.5 mm), silver chloride (AgCl, 99.99%) and platinum wire (ø = 1.0 
mm) used to prepare electrodes were purchased from Sigma–Aldrich 
(Steinheim, Germany). Scotch book tape (3M, St Paul, MN, USA) 
was used for tape stripping and cyanoacrylate superglue (Henkel 
Loctite, Dublin, Ireland) was used for follicles biopsies. Cellulose 
acetate membranes (cut off = 0.22 µm) were purchased from Fisher 
Scientific (Leicestershire, UK). HEPES salt and sodium chloride were 
from Acros (Berkeley, NJ, USA). The solvents used for extraction 
and chromatographic analysis were all of HPLC grade. The water 
used in all preparations was of Milli-Q grade (Millipore, Illkirch-
Graffenstaden, France).
Skin
Porcine ears were gently donated by a local abattoir (Bonasa 
Alimentos, São Sebastião, Brazil) and were obtained less than 1 h 
post-sacrifice of the animal. The whole skin was removed from the 
outer region of the ear, separated from its underlying layer, and used 
“full-thickness” to guarantee the intactness of the hair follicles. The 
skin was stored frozen at −20 °C for a maximum of 1 month before 
use.
Preparation of nanoparticles
MXS-NP were prepared by inducing the gelation of chitosan solu-
tions with a crosslink agent (TPP), as previously described.8 Briefly, 
8.75 mg of MXS was added to 5 mL of an acidified chitosan solution 
(containing 8.75 mg chitosan, 50 mg acetic acid), pH 5. Then, 2 mL 
of a TPP solution (at 1 mg mL-1) was added under constant magnetic 
stirring (700 rpm), resulting in the nanoparticles dispersion. The 
MXS-NP formed presented mean diameter of 200 ± 50 nm (PDI = 
0.25 ± 0.03), positive zeta potential of +23 ± 4 mV and entrapment 
efficiency of 72%.
Permeation studies protocol
Modified Franz diffusion cells were assembled with the skin of 
the porcine’s ear separating the donor to the receptor compartment. 
The receptor compartment was filled with 15 mL of HEPES buffer 
(pH 7.4). In the donor compartment, it was added 1 mL of (i) MXS-
NP formulation (1.25 mg mL-1 MXS, 0.53 mg mL-1 NaCl, pH 5.5), 
or (ii) MXS aqueous solution (1.25 mg mL-1 MXS, 0.53 mg mL-1 
NaCl, pH 5.5). Positive Ag electrode was placed in donor chamber 
(area = 1.3 cm2) in contact with formulation, while negative AgCl 
electrode was placed in receptor solution. A direct constant current 
of 0.65 mA (0.5 mA cm-2) was applied with the aid of a power source 
connected to the positive and negative electrodes (Sinewave generator, 
Model GCC20200, Piracicaba, Brazil). Passive experiments were also 
conducted with the same formulations but without the insertion of the 
electrodes. All experiments were conducted for 6 h, when receptor 
solution was withdrawn from the diffusion cells and analysed for 
MXS content in HPLC.
Recovery of MXS from skin layers
At the end of permeation experiments, the skin was removed 
from the diffusion cell and placed onto a flat surface with the stra-
tum corneum facing up. The skin was cleaned with a water-soaked 
gauze pad and tape-stripped 15 times, using Scotch book tapes. 
MXS content in the tapes was determined as described below after 
exhaustive extraction of the drug with methanol over a 24 h period. 
A drop of cyanoacrylate superglue was applied to the stripped skin 
area and covered with a further tape-strip using light pressure. After 
total polymerisation of the glue (∼5 min), this tape-strip was then 
removed and the skin surface biopsy obtained in this way contained 
follicular casts, from which MXS was extracted with methanol and 
quantified. Finally, reminiscent skin was cut into small pieces and 
placed in plastic tube along with methanol also over a period of 
24 h for drug extraction. The resulting suspensions were filtered on 
0.22 µm filters and quantified by HPLC.
The efficiency of recovery of MXS from the stratum corneum, 
follicular material and viable epidermis was previously determined, 
with MXS recovery values higher than 90%.
Influence of iontophoresis in MXS release
In this series of experiments, modified Franz-type diffusion cells 
were mounted with hydrophilic cellulose membranes separating the 
donor and receptor compartment, which was filled with 15 mL of 
HEPES buffer (pH 7.4). The cellulose membranes served here only 
as a support to the formulations. The release of MXS from 1 mL of 
MXS-NP formulation containing the equivalent to 1.25 mg/mL MXS 
(pH 5.5) was determined in vitro under the influence of anodal ion-
tophoresis or not over a period of 6 h. The iontophoresis experiment 
followed the protocol described in the previous section. Diffusion 
of MXS from an aqueous solution (1.25 mg mL-1, pH 5.5) through 
the cellulose acetate membrane was also determined as a control.
Release rates of MXS from MXS-NP with or without ionto-
phoresis application, as well as, from a simple MXS solution, were 
calculated from the slope of linear curves obtained by plotting amount 
of MXS released (µg cm-2) versus time (h), considering the 6 time 
points of each experiment. All release profiles followed zero order 
kinetics, with linear correlation coefficients (r) higher than 0.9 when 
amount of drug released is related with time.
HPLC analysis
The quantification of MXS was performed by a reversed-phase 
chromatographic method using a HPLC with UV detection, set at 
285 nm (model LC-20AD, Shimadzu, Kyoto, Japan). The operating 
conditions of the method were the following: 50 µL of injection volume; 
reverse-phase C18 column (Shimadzu, 4.6 mm × 15 mm, 5µm); water/
acetronitrile (80:20, v/v) as an isocratic mobile phase; and flow rate 
of 1.0 mL/min. The method was previously validated in accordance 
to FDA guidelines, and proved to be selective and linear (r = 0.9997). 
The LOQ and LOD were 0.5 µg mL-1 and 0.05 µg mL-1, respectively.
Statistical studies
At least five replicates of each quantitative experiment were 
performed. The results are presented in the text as means ± standard 
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deviations. The data were analysed by ANOVA followed by a non-
parametric Tukey’s test. The statistical significance was fixed at 
P < 0.05.
RESULTS AND DISCUSSION
The hypothesis to be tested in this paper was whether iontopho-
resis applied to a nanoparticle formulation could target the nanopar-
ticles to the follicular casts and whether, once nanoparticles were 
within the casts, they could sustain drug release, preventing dermal 
exposure. The rationale for this approach has been partially proven 
by our former publications: iontophoresis clearly targeted MXS to 
the follicular route, as it is the pathway with lower resistance under 
the influence of a potential gradient,9-11,17 and MXS-nanoparticles 
sustained drug release about twice more than previous prepared 
MXS-loaded microparticles.8,22
Figure 2 shows recovery of MXS from stratum corneum tape 
strips and follicular casts after 6 h of either passive or iontophoresis 
driven diffusion from the two tested formulations – free-drug solution 
and MXS-NP. The passive delivery study of MXS from the chitosan 
nanoparticles reflects previously published results of our group8 and 
is depicted here simply to serve as a control. 
MXS-NP have a positive zeta potential (+23 ± 4 mV), as a result 
of amino groups of the polymer chitosan, which at the acid pH of 
the formulation is positively charged. It was thereby supposed that 
an electrical current would improve accumulation of these positively 
charged nanoparticles into the hair follicles when the formulation 
was put in contact with the positive electrode in the anode compart-
ment. Present results, however, showed that the combination of these 
techniques did not provide the expected cumulative targeting effect. 
MXS accumulation in follicle casts following iontophoresis of the 
nanoparticles (4.1 ± 0.9 µg cm-2) was not higher (p>0.05) than drug 
amounts obtained after passive permeation of the MXS chitosan 
nanoparticles (5.3 ± 1.0 µg cm-2) or the iontophoretic delivery from 
the drug solution (4.7 ± 0.9 µg cm-2). This last result contrasts a study 
previously conducted by our group,9 in which the iontophoresis in-
creased 5 times the penetration MXS follicles from a gel formulation. 
However, besides it is a different formulation (poloxamer gel formula-
tion instead of a simple aqueous solution), the drug concentration in 
that gel formulation was 10-fold higher than this used here, which 
was prepared containing 1.25 mg mL-1 MXS to serve as a control for 
the formulation of nanoencapsulated drug.
Concerning dermal exposure, which is represented by drug 
amounts retained in viable skin and receptor solution (Figure 3), 
although it was significantly lower when the iontophoresis was 
applied to the nanoparticle formulation (15.2 ± 1.2 µg cm-2 and 
15.3 ± 4.3 µg cm-2, respectively) in comparison to the free drug 
solution (39.6 ± 6.9 µg cm-2 and 61.5 ± 13.4 µg cm-2, respectively) 
(p<0.05), the values were still higher than those obtained with the 
passive nanoparticle formulation delivery (2.5 ± 1.0 µg cm-2 in viable 
skin and no drug detected in receptor solution).
Results, therefore, show that there is no advantage on applying 
iontophoresis for alopecia treatment using these formulations. In fact, 
as dermal exposure is increased upon the application of the potential 
gradient, the risk of side effects is higher. A schematic representation 
of the results is presented in Figure 4.
Taveira et al.21 have explored the combination of iontophoresis 
with solid lipid nanoparticles loading doxorubicin and also observed 
that twice more drug was recovered from deeper layers of skin with 
this association compared to the passive delivery of the drug from the 
nanoparticles. In contrast to the rigid chitosan nanoparticles, how-
ever, solid lipid nanoparticles are deformable particles, which tend 
to accumulate in skin surface forming an occlusive film. This film 
increases stratum corneum hydration and, consequently, skin perme-
ability for encapsulated drugs.23 Furthermore; there is no evidence 
that lipid nanoparticles under influence of iontophoresis penetrate hair 
follicles, and the authors believe that under the influence of ionto-
phoresis, doxorubicin was released from the solid nanoparticles and 
Figure 2. MXS recovered from stratum corneum, hair follicles, after 6 h of 
either passive treatment with a simple MXS water solution (1.25 mg mL-1 
MXS, pH 5.5), passive treatment with MXS-loaded chitosan nanoparticles 
(1.25 mg mL-1 MXS, pH 5.5, 0.53 mg mL-1 NaCl), anodal iontophoresis applied 
in a MXS water solution (1.25 mg mL-1 MXS, pH 5.5, 0.53 mg mL-1 NaCl), 
anodal iontophoresis of MXS-loaded chitosan nanoparticles (1.25 mg mL-1 
MXS, pH 5.5, 0.53 mg mL-1 NaCl)
Figure 3. MXS recovered from viable dermis and receptor solution, after 6 h 
of either passive treatment with a simple MXS water solution (1.25 mg mL-1 
MXS, pH 5.5), passive treatment with MXS-loaded chitosan nanoparticles 
(1.25 mg mL-1 MXS, pH 5.5, 0.53 mg mL-1 NaCl), anodal iontophoresis applied 
in a MXS water solution (1.25 mg mL-1 MXS, pH 5.5, 0.53 mg mL-1 NaCl), ano-
dal iontophoresis of MXS-loaded chitosan nanoparticles (1.25 mg mL-1 MXS, 
pH 5.5, 0.53 mg/mL NaCl). *Amount below detection limit of analytical method
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permeated the skin under the influence of electroosmotic flow,23 i.e., 
a convective water flow towards the skin formed under the influence 
of an electric potential application.10,11
Indeed, our results can be explained by release rate of MXS from 
MXS-NP dispersion under the influence of iontophoresis. It has been 
clearly demonstrated in Table 1 that, under the influence of anodal 
iontophoresis, the nanoparticles are no longer able to sustain drug 
release, i.e. MXS release flux from nanoparticles formulation under 
influence of electric potential was not statistically different from 
free-drug diffusion through the cellulose membrane (p>0.05), but is 
considerably different from MXS release from chitosan nanoparticles 
without current application (p<0.05).
In this way, the use of an additional technology, as iontophore-
sis, which could increase therapy cost, is not justified for chitosan-
-nanoparticles loading MXS. Further studies employing different 
nanosystems are required to better understand nanoparticle behaviour 
under the influence of a potential gradient.
CONCLUSION
Even though iontophoresis presents comparable MXS targeting 
potential to hair follicles as nanoencapsulation, it is less effective on 
preventing dermal exposure, since the electric current accelerates 
drug release from the nanoparticles. The passive application of MXS-
loaded chitosan nanoparticles remains the best way to target MXS to 
the hair follicles while avoiding possible side effects.
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Table 1. MXS release rate calculated based on drug release profile from MXS-
-free solution, MXS-NP, and MXS-NP under the influence of iontophoresis 
(0.5 mA cm-2)
Formulation Release rate (µg cm-2 h-1) r
MXS-free solution 188.9 (± 6.0) 0.98
MXS-NP 35.4 (± 1.8) 0.91
MXS-NP iontophoresis 168.6 (± 14.1) 0.99
Figure 4. Schematic representation of the effects of formulation and iontopho-
resis application for topical MXS delivery: (a) passive delivery of free MXS, 
(b) passive delivery of MXS-loaded chitosan nanoparticles, (c) iontophoresis 
of free MXS target drug delivery to hair follicles, and (d) iontophoresis of 
MXS-loaded chitosan nanoparticles
